Cytokines and psoriasis: When cytokines become "pathokines"

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 6, 2007, Pages 679-690

  Somani, A K ^a   Yang, M F ^a   Cooper, K D ^a   Mccormick, T S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cytokines; Psoriasis, diagnosis; Psoriasis, physiopatology

Indexed keywords

ADALIMUMAB; CHEMOKINE; CYTOKINE; ETANERCEPT; GROWTH FACTOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 23; LYMPHOTOXIN; PLATELET DERIVED GROWTH FACTOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALLELE; ANTIGEN PRESENTING CELL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; KERATINOCYTE; LEUKOCYTE ACTIVATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 38849158604     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
2. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-7.
3. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.
4. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005:64 (Suppl 2):ii30-ii36.
5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
6. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
7. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006;8:355-63.
8. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.
9. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-28.
10. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007;57:347-54.
11. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9.
12. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912.
13. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004;22:349-69,vii.
14. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
15. Kirby B, Griffiths CE. Novel immune-based therapies for psoriasis. Br J Dermatol 2002;146:546-51.
16. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007;299:359-66.
17. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007;10:149-66.
18. Chin YH, Falanga V, Cai JP. Lymphocyte adhesion to psoriatic dermal endothelium: mechanism and modulation. J Invest Dermatol 1990;95:29S-31S.
19. Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity. J Autoimmun 2005;(25 Suppl):69-73.
20. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995;105:89S-94S.
21. Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP, Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997;151:1321-29.
22. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-23.
23. Bacharach-Buhles M, el GS, Panz B, Altmeyer P. In psoriasis the epidermis, including the subepidermal vascular plexus, grows downwards into the dermis. Br J Dermatol 1997;136:97-101.
24. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60.
25. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6.
26. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007;13:242-4.
27. Schon MP, Ruzicka T. Psoriasis: the plot thickens. Nat Immunol 2001;2:91.
28. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52.
29. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-6.
30. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-51.
31. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-73.
32. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001;2:102-7.
33. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
34. Kagen MH, McCormick TS, Cooper KD. Regulatory T cells in psoriasis. Ernst Schering Res Found Workshop 2006;193-209.
35. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25:195-201.
36. Ye P. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-27.
37. Matusevicius D. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4.
38. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589-93.
39. Hashimoto T, Akiyama K, Kobayashi N, Mori A. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy Immunol 2005;137:51-4.
40. Linden A, Hoshino H, Laan M. Airway neutrophils and interleukin-17. Eur Respir J 2000;15:973-7.
41. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51.
42. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
43. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273-9.
44. Li J, Chen X, Liu Z, Yue Q, Liu H. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci 2007;27:330-2.
45. Li J, Li D, Tan Z. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci 2004;24:294-6.
46. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567-79.
47. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75-87.
48. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
49. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
50. Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM. Biologic therapy for psoriasis: a brief history, II. Cutis 2001;68:367-72.
51. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000;165:4076-85.
52. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-73.
53. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000;14:63-78.
54. Schaerli P, Britschgi M, Keller M, Steiner UC, Steinmann LS, Moser B et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004;173:2151-8.
55. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 2000;24:212-25.
56. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:S94-100.
57. Yu Y, Tang L, Wang J, Liu S, Wang W, An H et al. Psoriatic lesional keratinocytes promote the maturation of human monocyte-derived Langerhans cells. Dermatology 2002;204:94-9.
58. Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol 2004;16:331-7.
59. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 2002;80:497-505.
60. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75.
61. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8.
62. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin Immunol 2005;17:273-83.
63. Cutler CW, Jotwani R, Pulendran B. Dendritic cells: immune saviors or Achilles' heel? Infect Immun 2001;69:4703-8.
64. Mrowietz U, Koch WA, Zhu K, Wiedow O, Bartels J, Christophers E et al. Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells. Exp Dermatol 2001;10:238-45.
65. Sozzani S, Allavena P, Vecchi A, Mantovani A. Chemokines and dendritic cell traffic. J Clin Immunol 2000;20:151-60.
66. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH et al. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest 2004;113:701-8.
67. Melief CJ. Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003;33:2645-54.
68. Goodman W, Massari J, McCormick T, Cooper K. Does IL-6 in psoriatic lesions reverse the ability of regulatory T cells to suppress effector T cell proliferation? J Invest Dermatol 2007;127:S125.
69. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
70. Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23:1081-92.
71. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
72. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F et al. Increased expression of interleukin 23p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
73. Clark RA, Kupper TS. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 2006;116:2084-7.
74. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Gnaes-Hansen F, Skov L et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003;112:1571-80.
75. Ruckert R, Asadullah K, Seifert M, Budagian VM, Arnold R, Trombotto C et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol 2000;165:2240-50.
76. Elder JT, Klein SB, Tavakkol A, Fisher GJ, Nickoloff BJ, Voorhees JJ. Growth factor and proto-oncogene expression in psoriasis. J Invest Dermatol 1990;95:7S-9S.
77. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12.
78. Chen SH, Arany I, Apisarnthanarax N, Rajaraman S, Tyring SK, Horikoshi T et al. Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha(2)-glycoprotein and cathepsin D. FASEB J 2000;14:565-71.
79. Ting KM, Rothaupt D, McCormick TS, Hammerberg C, Chen G, Gilliam AC et al. Overexpression of the oncofetal Fn variant containing the EDA splice-in segment in the dermal-epidermal junction of psoriatic uninvolved skin. J Invest Dermatol 2000;114:706-11.
80. Creamer JD, Barker JN. Vascular proliferation and angiogenic factors in psoriasis. Clin Exp Dermatol 1995;20:6-9.
81. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144:820-8.
82. Jiang WY, Chattedee AD, Raychaudhuri SP, Raychaudhuri SK. Farber EM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001;40:699-703.
83. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996;107:778-82.
84. Takematsu H, Tagami H. Granulocyte-macrophage colony-stimulating factor in psoriasis. Dermatologica 1990;181:16-20.
85. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9.
86. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-62.
87. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:392-7.
88. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 2004;25:295-305.
89. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40.
90. Nickoloff BJ, Schroder JM, von den DP, Raychaudhuri SP, Farber EM, Boehncke WH et al. Is psoriasis a T-cell disease? Exp Dermatol 2000;9:359-75.
91. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71.
92. Benoit S, Toksoy A, Ahlmann M, Schmidt M, Sunderkotter C, Foell D et al. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol 2006;155:62-6.
93. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B et al. Psoriasin: a novel chemotactic protein. J Invest Dermatol 1996;107:5-10.
94. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998;160:1427-35.
95. Newton RA, Thiel M, Hogg N. Signaling mechanisms and the activation of leukocyte integrins. J Leukoc Biol 1997;61:422-6.
96. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006;113:2278-84.
97. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005;280:41521-9.
98. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886-91.
99. O'kane M, Markham T, McEvoy AN, Fearon U, Veale DJ, Fitzgerald O et al. Increased Expression of the Orphan Nuclear Receptor NURR1 in Psoriasis and Modulation following TNF-alpha Inhibition. J Invest Dermatol 2007 Aug 2; [Epub ahead of print].
100. Baker BS, Swain AF, Griffiths CE, Leonard JN, Fry L, Valdimarsson H. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol 1985;61:526-34.
101. Baker BS, Griffiths CE, Lambert S, Powles AV, Leonard JN, Valdimarsson H et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987;116:503-10.
102. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005;102:2075-80.
103. Li X, Fan X, Zhang K, Yin G, Liu Y. Influence of psoriatic peripheral blood CD4+ T and CD8+ T lymphocytes on C-myc, Bcl-xL and Ki67 gene expression in keratinocytes. Eur J Dermatol 2007;17:392-6.
104. Raja Babu KK. Pharmacological interventions for psoriatic arthritis: present and future. Indian J Dermatol Venereol Leprol 2002;68:187-97.
105. Joshi R. Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol 2004;70:10-2.
106. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002;138:657-63.
107. Tutrone WD, Weinberg JM. Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept. Expert Rev Dermatol 2006;1:207-16.
108. Kurd SK, Richardson SK, Gelfand JM. Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol 2007;3:171-85.
109. Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 2007;12:5-8.
110. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK, III. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 2004;13:193-222.
111. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Rev Dermatol 2007;2:335-49.
112. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
113. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003;48:68-75.
114. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
115. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
116. Numerof RP, Asadullah K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 2006;20:93-103.
117. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26.